study_id,year,design,effect_type,effect_point,ci_low,ci_high,n_treat,n_ctrl,risk_of_bias,doi,journal_id,outcome,population,adverse_events,duration_weeks
REN-NSAID-MIT_01,2015,randomized controlled trial,SMD,0.3289,0.1692,0.4886,50,53,some concerns,10.1234/ren-nsaid-mit-01,renal_safety_journal,renal_risk_mitigation,Adults with renal risk mitigation concerns,Mild GI discomfort,10
REN-NSAID-MIT_02,2016,randomized controlled trial,SMD,0.3771,0.2443,0.5100,54,56,mixed,10.1234/ren-nsaid-mit-02,renal_safety_journal,renal_risk_mitigation,Adults with renal risk mitigation concerns,Transient headache,11
REN-NSAID-MIT_03,2017,randomized controlled trial,SMD,0.3817,0.2298,0.5336,58,59,low,10.1234/ren-nsaid-mit-03,renal_safety_journal,renal_risk_mitigation,Adults with renal risk mitigation concerns,None reported,6
